MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii
Launch of ARPEGE, a French multidisciplinary consortium to fight antibiotic resistance through preventive, diagnostic, therapeutic and economic approaches
Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project has been funded by the French government with nearly €9 million out of a total estimated budget of €17 million
Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens
ANT3310 is a novel, potent and specific inhibitor of bacterial Serine Beta-Lactamases (SBLs) which displays excellent inhibitory activity against both KPC and OXA carbapenemases. It will be administered intravenously in conjunction with meropenem, for treating hospital-acquired infections caused by Gram negative pathogens, including those that are carbapenem-resistant, notably carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant A. baumannii (CRAB), which are WHO Priority Pathogens.
Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens
QIDP is granted to MEM-ANT3310 for major hospital indications including nosocomial pneumonia
Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients
The funding will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studies.
The US government announced several significant changes to hospital antibiotic reimbursement by Medicare & Medicaid (CMS) in US hospitals.
Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681
The QIDP status provides ANT2681 with a five-year extension of data exclusivity as well as eligibility for Fast Track designation and priority review of its New Drug Application (NDA) for cUTI once submitted.
Antabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM Microbe Conference, June 20-24, San Francisco
Two presentations will focus on Antabio’s ANT2681, a novel Metallo β-Lactamase Inhibitor that restores the efficacy of Meropenem against clinical strains of NDM-producing CRE.
We are pleased to announce that Antabio’s CEO Marc Lemonnier has been appointed as a new member of the Scientific Advisory Board (SAB) of JPIAMR.
New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017.